The use of arrays in preimplantation genetic diagnosis and screening
|
|
- Elijah Craig
- 5 years ago
- Views:
Transcription
1 MODERN TRENDS Edward E. Wallach, M.D. Associate Editor The use of arrays in preimplantation genetic diagnosis and screening Joyce C. Harper, Ph.D., a and Gary Harton, B.S. b a Reader in Human Genetics and Embryology, University College London Centre for Preimplantation Genetics and Diagnosis, Institute for Women s Health, University College London and Centre for Reproductive and Genetic Health, Institute for Women s Health, University College London Hospital, London, United Kingdom; and b Preimplantation Genetic Diagnosis, Genetics & IVF Institute, Fairfax, Virginia Background: In preimplantation genetic diagnosis (PGD), polymerase chain reaction has been used to detect monogenic disorders, and in PGD/preimplantation genetic screening (PGS), fluorescence in situ hybridization (FISH) has been used to analyze chromosomes. Ten randomized controlled trials (RCTs) using FISH-based PGS on cleavage-stage embryos and one on blastocyst-stage embryos have shown that PGS does not increase delivery rates. Is the failure of PGS due to a fundamental flaw in the idea, or are the techniques that are being used unable to overcome their own, inherent flaws? Array-based technology allows for analysis of all of the chromosomes. Two types of arrays are being developed for use in PGD; array comparative genomic hybridization (acgh) and single nucleotide polymorphism based (SNP) arrays. Each array can determine the number of chromosomes, however, SNP-based arrays can also be used to haplotype the sample. Objective(s): To describe acgh and SNP array technology and make suggestions for the future use of arrays in PGD and PGS. Conclusion(s): If array-based testing is going to prove useful, three steps need to be taken: [1] Validation of the array platform on appropriate cell and tissue samples to allow for reliable testing, even at the single-cell level; [2] deciding which embryo stage is the best for biopsy: polar body, cleavage, or blastocyst stage; [3] performing RCTs to show improvement in delivery rates. If RCTs are able to show that array-based testing at the optimal stage for embryo biopsy increases delivery rates, this will be a major step forward for assisted reproductive technology patients around the world. (Fertil Steril Ò 2010;94: Ó2010 by American Society for Reproductive Medicine.) Key Words: PGD, PGS, CGH, array CGH, SNP arrays, mosaicism, embryo biopsy, ART Received November 11, 2009; revised April 20, 2010; accepted April 26, 2010; published online June 25, J.C.H. has nothing to disclose. G.H. has nothing to disclose. Dr. Harton s present address: Reprogenetics, 3 Regent Street, Suite 301, Livingston, NJ Reprint requests: Joyce Harper, UCL Centre for PG & D, Institute for Women s Health, University College London, Chenies Mews, London, WC1E 6HX, England (FAX: ; joyce.harper@ ucl.ac.uk). PREIMPLANTATION GENETIC DIAGNOSIS Preimplantation genetic diagnosis (PGD) for inherited disorders was first successfully applied in 1990, allowing couples carrying a genetic abnormality to have a normal child (1, 2). PGD makes use of routine IVF procedures to generate embryos in vitro. Three different embryo development stages have been described: polar bodies removed from the oocyte/zygote (polar body biopsy), blastomeres removed from cleavage-stage embryos (cleavage stage biopsy), or trophectoderm cells removed from the blastocyst (blastocyst biopsy). The sample removed from the oocyte/zygote or growing embryo is then tested using either polymerase chain reaction (PCR) or fluorescence in situ hybridization (FISH). PCRbased techniques are used to diagnose specific genetic disease, while FISH-based techniques have been used to analyze chromosomes for patients carrying chromosome abnormalities or for embryo sexing for patients carrying X-linked diseases. The European Society for Human Reproduction and Embryology (ESHRE) PGD Consortium has collected data on the use of PGD over the last 10 years including the diseases that have been diagnosed and the success of the procedure (3). PREIMPLANTATION GENETIC SCREENING (PGS) PGS was developed to try and improve pregnancy rates in certain groups of patients undergoing IVF procedures owing to infertility. Reported indications for PGS include patients with advanced maternal age, repeated miscarriage, repeated implantation failure, and severe male factor infertility (3). PGS was first reported by Verlinsky et al. (4) and Munne et al. (5) in the analysis of polar bodies. Since these first reports, there have been numerous papers on the use of PGS; however, as with many new technologies brought into the IVF clinic, there has been little evidence to show that PGS increases delivery rates. There are now 11 randomized controlled trials (RCTs) applied to both good- (6 10) and /$36.00 Fertility and Sterility â Vol. 94, No. 4, September doi: /j.fertnstert Copyright ª2010 American Society for Reproductive Medicine, Published by Elsevier Inc.
2 poor- (11 16) prognosis patients. None of these trials have shown that PGS improved the delivery rate compared with a control group, while some have actually shown that PGS decreased the delivery rate. All of these studies used FISH-based techniques to study 5 12 chromosomes, and almost all were applied to cleavage-stage embryos, except Jansen et al. (8), who performed trophectoderm biopsy. The vast majority of randomized and nonrandomized studies on PGS have been performed with biopsy at the cleavage stage, which may be part of the reason for the poor performance of PGS so far. Embryos at this stage of development show high levels of chromosome abnormality and mosaicism (17, 18), therefore, analysis of one cell from a cleavage-stage embryo may not be representative of the genetic status of the whole embryo. In addition, almost all of these studies have used FISH-based testing of a limited number of chromosomes. Interphase FISH was developed and optimized for use on samples with many hundreds of cells to count, allowing for natural variations in hybridization efficiency, signal overlap, and other technical issues to be washed out over the whole analysis of the sample. While a few cells may have an aberrant count for a particular FISH probe due to technical issues, the majority of the cells will have the actual count allowing for diagnosis of the sample. FISH was not designed to test a sample set of one cell, therefore technical limitations of the test are magnified and will lead to false-positive and false-negative results, which will further affect the ability of FISH-based testing in PGS. It is no wonder that the above RCTs using FISH-based testing on cleavage-stage embryos have shown no improvements in delivery rates. Now is the time to assess the timing of biopsy and to find new methods that are able to analyze all of the chromosomes. Biopsy at the polar body or blastocyst stage and new testing methods including metaphase comparative genomic hybridization (m-cgh), array-cgh (a-cgh), and single nucleotide polymorphism (SNP) arrays must be investigated and rigorously tested, ushering in a new stage in PGD and PGS. COMPARATIVE GENOMIC HYBRIDIZATION Comparative genomic hybridization (CGH) is a technique that bridges the gap between molecular genetics and cytogenetics (19). In CGH, DNA from the test sample and DNA from a normal control DNA are amplified separately using a whole genome amplification (WGA) approach such as degenerate oligonucleotide primer PCR (20, 21), primer extension preamplification (PEP) PCR (22), or newer methods such as ipep (23), multiple displacement amplification (MDA) (24, 25), or GenomePlex (26). WGA application on single cells for PGD have been reported both for clinical and research purposes (27 32). To date, there does not seem to be a universal WGA that can be used for any arraybased platform. For CGH, the amplified DNA is differentially labeled with one of two fluorochromes, for example, red for the test DNA and green for the control DNA. After labeling, both DNAs are mixed together in equal proportions and are allowed to compete to hybridize to either metaphase spreads from a normal male control cell line (m-cgh) or onto an array platform containing small pieces of chromosome (a-cgh) (Fig. 1). In m-cgh, specialized computer software analyzes the ratio of red-to-green fluorescence along the length of each metaphase chromosome in about six different metaphase sets and plots the ratios on an ideogram. Gains in red indicate that the test sample is deficient in that region or chromosome, and gains in green indicate that the test has extra copies of that region or chromosome. The process is time-consuming and technically challenging, taking up to 72 hours to perform the laboratory bench work, with additional time required for the detailed analysis of the data. Array-CGH works on the same principal as m-cgh but uses a chip of DNA (usually bacterial artificial chromosomes [BACs]) affixed to the microscope slide instead of metaphase chromosomes and has been applied to single cells and embryos (25, 33, 34). Each BAC clone corresponds to a specific part of a chromosome and computer software analyzes the ratio of red and green fluorescence on each spot that will correspond to a loss or gain of that region, similar to m-cgh. The analysis is fully automated, and the whole procedure can be performed within 24 hours. For day 3 biopsy, it is possible to perform the ET on day 5 of embryo development in a fresh cycle. However, for some groups, especially those performing blastocyst biopsy and/or transport PGD, it may be preferable to freeze the biopsied embryos while the diagnosis and analysis is performed. Clinically, m-cgh has been applied in PGS patients at the polar body stage (35), the cleavage stage (36), and the blastocyst stage (37, 38). Owing to the time-consuming nature of m-cgh, the studies on cleavage-stage embryos and blastocysts required cryopreservation of embryos to allow time for genetic testing. Schoolcraft et al. (37) performed embryo biopsy at the blastocyst stage, with vitrification of all biopsied embryos during genetic testing. Chromosomally normal embryos were warmed and transferred in a subsequent controlled cycle. In this study, 45 patients underwent testing as outlined above. The main outcome measure of the study, implantation rate, was significantly increased in the study population when compared with a control set of patients that were well matched for most clinical parameters; however, there was a high multiple pregnancy rate (70%) and no increase in delivery rates. This same group is currently undertaking a three-armed RCT to further elucidate the benefits of testing using blastocyst biopsy and mcgh for comprehensive chromosome screening (CCS). Since mcgh takes several days to perform, embryo freezing is required. In this new study, the patients will be randomized into one of three groups: no treatment (day 5 blastocyst biopsy); day 5 blastocyst biopsy with CCS and vitrification of embryos for transfer in a subsequent, nonstimulated cycle; and no biopsy or testing but vitrification of all blastocysts on day 5 and day 6 with subsequent transfer in a nonstimulated cycle. In addition, Schoolcraft and colleagues are working on a number of follow-up papers to further discuss their data and findings (personal communication). Array-CGH is just beginning to be applied clinically to patients (39). In this study, a total of 41 embryos were assessed with a-cgh from eight PGS cycles, with pregnancy achieved in five of six cycles that had an ET. While CGH-based tests have been applied more rapidly in the assisted reproductive technology (ART) world than other array-based tests, there are some shortfalls of using CGH-based technology. Array-CGH cannot detect polyploidies, such as triploidies, as there is no imbalance in the total DNA content. In addition, CGH tests cannot detect balanced translocations or inversions as the total amount of DNA in the sample is the same as in the control sample. These systems cannot detect changes in DNA sequences (point mutations, intragenic insertions or deletions, triplet repeat expansion, etc.) or gains or losses in regions of the genome not covered by the array. SINGLE NUCLEOTIDE POLYMORPHISM ARRAYS Single nucleotide polymorphisms (SNP) are areas of the genome in which a single nucleotide in the sequence varies within the population. Most SNPs are biallelic; they exist in either of two 1174 Harper and Harton Use of arrays in PGD and PGS Vol. 94, No. 4, September 2010
3 FIGURE 1 (A) Metaphase CGH and (B) array CGH. First the biopsied material undergoes WGA and the embryonic DNA is labeled in green fluorescence. A control sample is labeled in red fluorescence. The samples are then cohybridized onto either (A) a metaphase spread or (B) an array platform. In both cases, a computer analyzes the ratio of red-to-green fluorescence. Courtesy of Thalia Mamas and Leoni Xanthopoulou, University College London Centre for PG&D. Harper. Use of arrays in PGD and PGS. Fertil Steril forms and occur over the entire genome. SNP arrays can use this information to distinguish one person from another and can be drilled down further to distinguish one chromosome from another in any person. A typical SNP array will have hundreds of thousands of SNPs to assess and, with the correct software, can distinguish how many of each chromosome was inherited by an embryo using both quantitative information and/or analyzing the expected combinations of inherited chromosomes and comparing them with the actual outcome (40). SNP arrays are based mainly in molecular genetics and rely on a WGA step to amplify the single cell or small number of cells removed from a developing embryo (34, 41, 42). Newer methods of performing WGA like MDA and GenomePlex are used for most applications of SNP arrays. These WGA methods tend to allow for better overall coverage of the genome and are less inclined to preferentially amplify some parts of the genome while leaving others unamplified or under amplified. After amplification, the DNA is labeled with red and green fluorescent molecules with one version of the SNP in red and the other version of the SNP in green. This DNA is then assessed for intensity of signal and number of SNP calls and compared with a control population by powerful computer software to allow for diagnosis of inheritance. SNP arrays are just beginning to be used clinically in PGD, although no publications have appeared in the literature as of yet. A number of groups around the world are currently validating SNP arrays and analysis software for clinical use in PGD. It is expected that clinical data from SNP arrays will closely match the data from CGH testing for PGS applications. While they use different technology to analyze the genome, both systems are essentially answering the same question: how many of each chromosome is present in asample? SNP-based arrays offer other options for testing that are not available on CGH-based systems. SNP-based arrays, owing to the data that are collected and the way they are analyzed, allow for simultaneous testing of specific genetic diseases and aneuploidy in each embryo. This will allow for the selective transfer of genetically and chromosomally normal embryos for patients undergoing IVF with PGD for monogenic diseases. Simple haplotyping of SNPs surrounding and embedded in disease-causing genes allows for selection of embryos that have not inherited the affected chromosome. In addition, simple haplotyping of various markers around the genome allow for analysis of live-born children to determine which embryo or embryos implanted in any given ART cycle. This last test may help IVF centers develop technology to assess an embryo s implantation potential that can be added on to tests for genetic and chromosomal normalcy, allowing for increased implantation and delivery rates in IVF centers around the world. With most countries moving toward single ET, a set of tests that pinpoints the one best embryo for transfer would be a welcome addition. Fertility and Sterility â 1175
4 ETHICAL ISSUES FOR SNP ARRAYS SNP arrays, owing to the vast amount of information gathered from each test, do pose the risk of additional ethical issues. Most scientists and clinicians agree that testing for inheritance of monogenic diseases is acceptable, and PGD has been proven to be an effective method to test embryos. More debate surrounds the idea of aneuploidy screening (43, 44, 45) and testing for inheritance of predisposition to disease (i.e., BRCA1 screening in embryos). SNP arrays could allow for analysis of other, less certain, inheritance patterns for multifactorial diseases such as diabetes as well as autism or heart disease. These types of tests will require much more validation and will certainly generate even more debate. While the data may be available from SNP arrays, we may not know enough about these conditions to safely test for them. CLINICAL ISSUES While both platforms listed above offer advantages over current technology, they both also come with a set of issues that need to be overcome before they can be placed into widespread clinical use. Beyond the need for proof in an RCT of the efficacy (increased delivery rate vs. not testing) of testing embryos for aneuploidy, there are practical issues that cannot be ignored. To perform CCS on day 5 or day 6 embryos, embryology laboratories must be proficient at blastocyst culture. New formulations of medium for embryo culture have allowed many embryology labs to move toward longer development in vitro with transfer of blastocysts on day 5 of development becoming more practical, but by no means is this routine in all IVF centers. Beyond culture to the blastocyst stage, blastocyst biopsy is performed clinically in a small number of labs around the world at this time, therefore most IVF centers will most likely not be able to offer biopsy at this stage of embryo development. Training on blastocyst culture and biopsy by experts will happen, but it will take some time to develop widescale use in IVF centers around the world. Analysis using chip-based platforms can be performed in 24 hours. If polar body or cleavage-stage biopsy is used, this should allow ample time to perform the diagnosis. However, if blastocyst biopsy and/or transport PGD is used, laboratories will need to be proficient at cryopreserving embryos immediately after biopsy. Two different methods of cryopreservation are widely used in embryology labs, slow cooling and vitrification. Both methods seem to offer advantages and disadvantages when compared, and no real best method has been decided on at this time. The dogma of assisted reproduction is that fresh transfer of embryos is always better than frozen, however, with current techniques, the gap may be closing. As referenced above, one planned RCT using metaphase CGH will include an arm that looks at cryopreservation of untested embryos to determine the effect (perhaps benefit) of this part of recent studies. It could be argued that some of the success of donor egg IVF comes from the fact that the embryos are being transferred into a uterus that has not seen exogenous FSH and has been prepared and monitored for uterine lining development. None of the issues discussed above are insurmountable, however, they do offer a number of hurdles that must be cleared before blastocyst biopsy and array-based testing can become routine in any IVF center around the world. WHAT NEXT FOR PGS? There are three questions we need to ask before applying any type of array clinically for PGS: 1. Which type of array would be the best for PGD/PGS and have the arrays been validated on embryonic samples, including polar bodies, single blastomeres, and trophectoderm cells? 2. At what stage should we do the biopsy for PGS? The answer to this question seems to be pointing away from cleavage stage and toward polar body or trophectoderm biopsy. 3. Has an RCT shown that this technology coupled with the biopsy stage statistically improves delivery rates? ESHRE PGS TASK FORCE PILOT AND RCT ESHRE is undertaking its first ever clinical trial a two-stage study developed to assess the efficacy of PGS using polar body biopsy and analysis of 24 chromosomes using array technology (45). The first part of the study aims to determine whether the technique of polar body biopsy and analysis of 24 chromosomes by array CGH is feasible. Any abnormal oocytes will also be examined to see whether the polar body abnormalities can really be used to predict that the oocyte will be abnormal. If the proof of principle part of the study is successful, the second part of the study will involve a multicenter RCT involving at least six centers in different European Union countries to determine whether PGS gives an increased delivery rate in women of advanced maternal age. It was decided to run the trial on polar bodies as this will allow for a fresh transfer, the biopsy is less invasive, and hopefully the results will be more reliable than cleavage or blastocyst biopsy as mosaicism will not affect the results. CONCLUSION The scientific basis of aneuploidy screening, removing chromosomally abnormal embryos from the cohort of embryos available after IVF, seems to be sound; however, proof of the concept is lacking (44). Recent studies (37) have renewed hope that new techniques (testing of 24 chromosomes instead of 8 12) and a fresh look at the moment of biopsy (moving away from cleavage stage where mosaicism is rampant) may finally show the usefulness of aneuploidy screening. It remains to be seen, in an RCT, whether PGS will improve delivery rates over traditional IVF with transfer of the bestlooking embryo. If the RCTs show that PGS using arrays improves delivery rates, this will be great news for IVF patients. The cost of arraybased testing, which at this time is higher than conventional methods, needs to be taken into account and will hopefully continue to drop as most new technologies do. Timing of embryo biopsy, as well as the ability to grow blastocysts and vitrify or freeze them after biopsy, are hurdles some IVF centers will struggle to overcome. There are concerns about the slippery slope that the SNP-based testing may bring, however, the promise of a test that will be able to assess a cohort of embryos and allow the choice of the one best embryo for transfer will be a huge leap forward for IVF centers around the world. It is hoped that other IVF/PGD centers will undertake rigorous RCTs to validate the use of PGS and only use techniques in clinical practice with appropriate evidence-based data. There is a lesson to be learned from the application of PGS in the early days, its clinical use, and the debate that has followed the RCTs published to date (44) Harper and Harton Use of arrays in PGD and PGS Vol. 94, No. 4, September 2010
5 REFERENCES 1. Handyside AH, Kontogianni EH, Hardy K, Winston RML. Pregnancies from biopsied human preimplantation embryos sexed by Y-specific DNA amplification. Nature 1990;244: Harper JC. Preimplantation genetic diagnosis. Cambridge: Cambridge University Press, Goossens V, Harton G, Moutou C, Traeger- Synodinos J, Van Rij M, Harper JC. ESHRE PGD Consortium data collection IX: cycles from January to December 2006 with pregnancy follow-up to October Hum Reprod 2009;24: Verlinsky Y, Cieslak J, Freidine M, Ivakhnenko V, Wolf G, Kovalinskaya L, et al. Pregnancies following pre-conception diagnosis of common aneuploidies by fluorescent in-situ hybridization. Hum Reprod 1995;10: Munne S, Dailey T, Sultan KM, Grifo J, Cohen J. The use of first polar bodies for preimpantation diagnosis of aneuploidy. Hum Reprod 1995;10: Staessen C, Verpoest W, Donoso P, Haentjens P, Van der Elst J, Liebaers I, et al. Preimplantation genetic screening does not improve delivery rate in women under the age of 36 following single-embryo transfer. Hum Reprod 2008;23: Meyer LR, Klipstein S, Hazlett WD, Nasta T, Mangan P, Karande VC. A prospective randomized controlled trial of preimplantation genetic screening in the good prognosis patients. Fertil Steril 2009;91: Jansen RPS, Bowman MC, de Boer KA, Leigh DA, Lieberman DB, McArthur SJ. What next for preimplantation genetic screening (PGS)? Experience with blastocyst biopsy and testing for aneuploidy. Hum Reprod 2008;23: Mersereau JE, Pergament E, Zhang X, Milad MP. Preimplantation genetic screening to improve in vitro fertilization pregnancy rates: a prospective randomized controlled trial. Fertil Steril 2008;90: Blockeel C, Schutyser V, De Vos A, Verpoest W, De Vos M, Staessen C, et al. Prospectively randomised controlled trial of PGS in IVF/ICSI patients with poor implantation. Reprod Biomed Online 2008;17: Staessen C, Platteau P, Van Assche E, Michiels A, Tournaye H, Camus M, et al. Comparison of blastocyst transfer with or without preimplantation genetic diagnosis for aneuploidy screening in couples with advanced maternal age: a prospective randomized controlled trial. Hum Reprod 2004;19: Stevens J, Wale P, Surrey ES, Schoolcraft WB, Gardner DK. Is aneuploidy screening for patients aged 35 or over beneficial? A prospective randomized trial. Fertil Steril 2004;82:S249 S Debrock S, Melotte C, Spiessens C, Peeraer K, Vanneste E, Meeuwis L, et al. Preimplantation genetic screening for aneuploidy of embryos after in vitro fertilization in women aged at least 35 years: a prospective randomized trial. Fertil Steril 2010;93: Hardarson T, Hanson C, Lundin K, Hillensj o T, Nilsson L, Stevic J, et al. Preimplantation genetic screening in women of advanced maternal age caused a decrease in clinical pregnancy rate: a randomised controlled trial. Hum Reprod 2008;23: Mastenbroek S, Twisk M, van Echten-Arends J, Sikkema-Raddatz B, Korevaar JC, Verhoeve HR, et al. In vitro fertilization with preimplantation genetic screening. N Engl J Med 2007;357: Schoolcraft WB, Katz-Jaffe MG, Stevens J, Rawlins M, Munne S. Preimplantation aneuploidy testing for infertile patients of advanced maternal age: a randomized prospective trial. Fertil Steril 2009;92: Harper JC, Coonen E, Handyside AH, et al. Mosaicism of autosomes and sex chromosomes in morphologically normal, monospermic preimplantation human embryos. Prenat Diagn 1995;15: Munne S, Sultan KM, Weier HU, et al. Assessment of numeric abnormalities of X, Y, 18, and 16 chromosomes in preimplantation human embryos before transfer. Am J Obstet Gynecol 1995;172: Kallioniemi A, Kallioniemi OP, Sudan D. Comparative genomic hybridisation for molecular cytogenetic analysis of solid tumours. Science 1992;258: Telenius H, Carter NP, Bebb CE, Nordenskj old M, Ponder BA, Tunnacliffe A. Degenerate oligonucleotide-primed PCR: general amplification of target DNA by a single degenerate primer. Genomics 1992;13: Hu DG, Webb G, Hussey N. Aneuploidy detection in single cells using DNA array-based comparative genomic hybridization. Mol Hum Reprod 2004;10: Zhang L, Cui X, Schmitt K, Hubert R, Navidi W, Arnheim N. Whole genome amplification from a single cell: implications for genetic analysis. Proc Natl Acad Sci U S A 1992;89: Dietmaier W, Hartmann A, Wallinger S, Heinmoller E, Kerner T, Endl E, et al. Multiple mutation analyses in single tumor cells with improved whole genome amplification. Am J Pathol 1999;154: Dean FB, Hosono S, Fang L, et al. Comprehensive human genome amplification using multiple displacement amplification. Proc Natl Acad Sci U S A 2002;99: LeCaignec C, Spits C, Sermon K, De Rycke M, Thienpont B, Debrock S, et al. Single-cell chromosomal imbalances detection by array CGH. Nucleic Acids Res 2006;34:e Fiegler H, Geigl JB, Langer S, Rigler D, Porter K, Unger K, et al. High resolution array- CGH analysis of single cells. Nucleic Acids Res 2007;35:e Wilton L, Voullaire L, Sargeant P, Williamson R, McBain J. Preimplantation aneuploidy screening using comparative genomic hybridization of fluorescence in situ hybridization of embryos from patients with recurrent implantation failure. Fertil Steril 2003;80: Hellani A, Coskun S, Tbakhi A, Al-Hassan S. Clinical application of multiple displacement amplification in preimplantation genetic diagnosis. Reprod Biomed Online 2005;10: Renwick PJ, Lewis CM, Abbs S, Ogilvie CM. Determination of the genetic status of cleavagestage human embryos by microsatellite marker analysis following multiple displacement amplification. Prenat Diagn 2007;27: Lledo B, Ten J, Galan FM, Bernabeu R. Preimplantation genetic diagnosis of Marfan syndrome using multiple displacement amplification. Fertil Steril 2006;86: Burlet P, Frydman N, Gigarel N, et al. Multiple displacement amplification improves PGD for fragile X syndrome. Mol Hum Reprod 2006;12: Ren Z, Zhou C, XuY, Deng J, Zeng H, Zeng Y. Mutation and haplotype analysis for Duchenne muscular dystrophy by single cell multiple displacement amplification. Mol Hum Reprod 2007;13: Fiegler H, Redon R, Andrews D, Scott C, Andrews R, Carder C, et al. Accurate and reliable high-throughput detection of copy number variation in the human genome. Genome Res 2006;16: Vanneste E, Voet T, Le Caignec C, Ampe M, Konings P, Melotte C, et al. Chromosome instability is common in human cleavage-stage embryos. Nat Med 2009;15: Wells D, Escudero T, Levy B, Hirschhorn K, Delhanty JD, Munne S. First clinical application of comparative genomic hybridization and polar body testing for preimplantation genetic diagnosis of aneuploidy. Fertil Steril 2002;78: Wilton L, Williamson R, McBain J, Edgar D, Voullaire L. Birth of a healthy infant after preimplantation confirmation of euploidy by comparative genomic hybridization. N Engl J Med 2001;345: Schoolcraft WB, Fragouli E, Stevens J, Munne S, Katz- Jaffe MG, Wells D. Clinical application of comprehensive chromosomal screening at the blastocyst stage. Fertil Steril [Epub ahead of print]. 38. Hellani A, Abu-Amero K, Azouri J, El-Akoum S. Successful pregnancies after application of arraycomparative genomic hybridization in PGSaneuploidy screening. Reprod Biomed Online 2008;17: Handyside AH, Harton G, Mariani B, Thornhill AR, Affara NA, Shaw MA, et al. Karyomapping: a universal method for genome crossovers between parental haplotypes wide analysis of genetic disease based on mapping. J Med Genet [Epub ahead of print]. 40. Treff NR, Su J, Mavrianos J, Bergh PA, Miller KA, Scott RT Jr. Accurate 23 chromosome aneuploidy screening in human blastomeres using single nucleotide polymorphism (SNP) microarrays. Fertil Steril 2007;86:S Kearns WG, Pen R, Benner A, Kittai A, Widra E, Leach R. SNP microarray genetic analyses to determine 23-chromosome ploidy, structural chromosome aberrations and genome-wide scans to identify disease risks from a single embryonic cell. Fertil Steril 2008;90:S Harper JC, Sermon K, Geraedts J, et al. What next for preimplantation genetic screening. Hum Reprod 2008;23: Harper JC, Coonen E, De Rycke M, Geraedts J, Goosens V, Harton G, et al. What next for preimplantation genetic screening (PGS)? A position statement from the ESHRE PGD Consortium steering committee. Hum Reprod 2010;25: Munne S, Gianaroli L, Tur-Kaspa I, Magli C, Sandalinas M, Grifo J, et al. Substandard application of preimplantation genetic screening may interfere with its clinical success. Fertil Steril 2007;88: Geraedts J, Collins J, Devroey P, Gianaroli L, Goossens V, Handyside A, et al. What next for preimplantation genetic screening? A polar body approach!. Hum Reprod 2010;25(3): Fertility and Sterility â 1177
An Update on PGD: Where we are today
An Update on PGD: Where we are today Joyce Harper UCL Centre for PG&D and CRGH Institute for Womens Health University College London Overview What is PGD/PGS How we do it Disadvantages and advantages Future
More informationPerspectives on the efficacy and indications for preimplantation genetic screening: where are we now?
Human Reproduction Vol.23, No.12 pp. 2617 2621, 2008 doi:10.1093/humrep/den400 EDITORIAL COMMENTARY Perspectives on the efficacy and indications for preimplantation genetic screening: where are we now?
More informationChromosomal Aneuploidy
The Many Advantages of Trophectoderm Biopsy Compared to Day 3 Biopsy for Pre- Implantation Genetic Screening (PGS) Mandy Katz-Jaffe, PhD Chromosomal Aneuploidy Trisomy 21 Fetus Aneuploidy is the most common
More informationPreimplantation Genetic Testing
Protocol Preimplantation Genetic Testing (40205) Medical Benefit Effective Date: 01/01/14 Next Review Date: 09/14 Preauthorization No Review Dates: 09/11, 09/12, 09/13 The following Protocol contains medical
More informationIndications for chromosome screening Dagan Wells, PhD, FRCPath dagan.wells@obs-gyn.ox.ac.ukgyn.ox.ac.uk Chromosome imbalance (aneuploidy) Uncontroversial data The incidence of aneuploidy Aneuploidy is
More informationProblem Challenge Need. Solution Innovation Invention
Problem Challenge Need Solution Innovation Invention Tubal Infertility In-vitro Fertilisation Steptoe and Edwards Birth after the reimplantation of a human embryo. Lancet 1978 Louise Brown, 25. Juli 1978
More informationSNP microarray-based 24 chromosome aneuploidy screening is significantly more consistent than FISH
Molecular Human Reproduction, Vol.16, No.8 pp. 583 589, 2010 Advanced Access publication on May 19, 2010 doi:10.1093/molehr/gaq039 NEW RESEARCH HORIZON Review SNP microarray-based 24 chromosome aneuploidy
More informationClinical application of comprehensive chromosomal screening at the blastocyst stage
Clinical application of comprehensive chromosomal screening at the blastocyst stage William B. Schoolcraft, M.D., a Elpida Fragouli, Ph.D., b,c John Stevens, M.S., a Santiago Munne, Ph.D., d Mandy G. Katz-Jaffe,
More informationReview Preimplantation testing for chromosome aneuploidy
Review 2008;10:88 92 10.1576/toag.10.2.088.27396 www.rcog.org.uk/togonline The Obstetrician & Gynaecologist Review Preimplantation testing for chromosome aneuploidy Author Caroline Mackie Ogilvie Key content:
More informationOrganisation of the PGD Centre. Overview. Setting up a PGD centre
Organisation of the PGD Centre Joyce Harper Chair of the ESHRE PGD Consortium Overview Setting up a PGD Centre Organisation of the PGD Centre Preparation for clinical PGD Misdiagnosis Accreditation External
More informationESHRE PGD consortium best practice guidelines for fluorescence in situ hybridization-based PGD
Human Reproduction, Vol.00, No.0 pp. 1 8, 2010 doi:10.1093/humrep/deq230 ESHRE PAGES ESHRE PGD consortium best practice guidelines for fluorescence in situ hybridization-based PGD G.L. Harton 1,,*, J.C.
More informationThe role of the PGD Consortium. Overview. ESHRE PGD Consortium - Aims
The role of the PGD Consortium Joyce Harper Chair of the ESHRE PGD Consortium Overview Aims Membership Data Pregnancies Guidelines Training courses/education/post congress workshops Working groups PGS
More informationAccurate single cell 24 chromosome aneuploidy screening using whole genome amplification and single nucleotide polymorphism microarrays
Accurate single cell 24 chromosome aneuploidy screening using whole genome amplification and single nucleotide polymorphism microarrays Nathan R. Treff, Ph.D., a,b Jing Su, M.Sc., a Xin Tao, M.Sc., a Brynn
More informationAccuracy of FISH analysis in predicting chromosomal status in patients undergoing preimplantation genetic diagnosis
Accuracy of FISH analysis in predicting chromosomal status in patients undergoing preimplantation genetic diagnosis Catherine M. DeUgarte, M.D., a Man Li, M.D., Ph.D., b Mark Surrey, M.D., c Hal Danzer,
More informationArticle Successful pregnancies after application of array-comparative genomic hybridization in PGS-aneuploidy screening
RBMOnline - Vol 17 No 6. 2008 841-847 Reproductive BioMedicine Online; www.rbmonline.com/article/3419 on web 30 October 2008 Article Successful pregnancies after application of array-comparative genomic
More informationSame Day, Cost-Effective Aneuploidy Detection with Agilent Oligonucleotide array CGH and MDA Single Cell Amplification Method
Same Day, Cost-Effective Aneuploidy Detection with Agilent Oligonucleotide array CGH and MDA Single Cell Amplification Method Presenter: Dr. Ali Hellani, Founder, Viafet Genomic Center, Dubai Wednesday,
More informationSNP array-based analyses of unbalanced embryos as a reference to distinguish between balanced translocation carrier and normal blastocysts
J Assist Reprod Genet (2016) 33:1115 1119 DOI 10.1007/s10815-016-0734-0 TECHNOLOGICAL INNOVATIONS SNP array-based analyses of unbalanced embryos as a reference to distinguish between balanced translocation
More informationPreimplantation genetic diagnosis: polar body and embryo biopsy
Human Reproduction, Vol. 15, (Suppl. 4), pp. 69-75, 2000 Preimplantation genetic diagnosis: polar body and embryo biopsy Luca Gianaroli SISMER, Via Mazzini 12, 40138 Bologna, Italy Scientific Director
More informationEmbryoCellect TM. Pre-implantation Genetic Screening Kit TECHNICAL INFORMATION
EmbryoCellect TM Pre-implantation Genetic Screening Kit TECHNICAL INFORMATION Aneuploidy Whole chromosome aneuploidy has been shown to affect all chromosomes in IVF embryos. Aneuploidy is a significant
More informationValidation of microarray comparative genomic hybridization for comprehensive chromosome analysis of embryos
Validation of microarray comparative genomic hybridization for comprehensive chromosome analysis of embryos Cristina Gutierrez-Mateo, Ph.D., a Pere Colls, Ph.D., a Jorge Sanchez-Garcıa, Ph.D., a Tomas
More informationDevelopment of new comprehensive
Development and validation of an accurate quantitative real-time polymerase chain reaction based assay for human blastocyst comprehensive chromosomal aneuploidy screening Nathan R. Treff, Ph.D., a,b Xin
More informationOriginal Policy Date
MP 2.04.77 Preimplantation Genetic Testing Medical Policy Section OB/Gyn/Reproduction Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return to
More informationClinical applications of preimplantation genetic testing
Clinical applications of preimplantation genetic testing Paul R Brezina, 1 2 William H Kutteh 1 2 1 Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Vanderbilt
More information1 PGS (PGS) IVF PGS, PGS,, PGS 2, PGS : (PGS); PGS; ; : R321.1 : A : X(2015) PGS 1995, 1 , (ART)
35 2 Vol.35 No.2 2015 2 Feb. 2015 Reproduction & Contraception doi: 10.7669/j.issn.0253-357X.2015.02.0114 E-mail: randc_journal@163.com 1 123 (1. 200011) (2. 200011) (3. 200011) () IVF 2 : () : R321.1
More informationTargeted qpcr. Debate on PGS Technology: Targeted vs. Whole genome approach. Discolsure Stake shareholder of GENETYX S.R.L
Antonio Capalbo, PhD Laboratory Director GENETYX, reproductive genetics laboratory, Italy PGT responsible GENERA centers for reproductive medicine, Italy Debate on PGS Technology: Targeted vs. Whole genome
More informationUSA: Livingston, NJ. PGD for infertility. Europe: Barcelona, Spain Oxford, UK Hamburg, Germany. Asia: Kobe, Japan. South America: Lima, Peru
PGD for infertility Santiago Munné USA: Livingston, NJ Europe: Barcelona, Spain Oxford, UK Hamburg, Germany Asia: Kobe, Japan South America: Lima, Peru The majority of embryos with good morphology are
More informationTips and Tricks in Fluorescence In-situ Hybridization (FISH)- based Preimplantation Genetic Diagnosis /Screening (PGD/PGS)
International Journal of Medical Laboratory 2018;5(2):84-98. Review Article Tips and Tricks in Fluorescence In-situ Hybridization (FISH)- based Preimplantation Genetic Diagnosis /Screening (PGD/PGS) Fatemeh
More informationTechnical Update: Preimplantation Genetic Diagnosis and Screening
No. 323, May 2015 (Replaces No. 232, August 2009) Technical Update: Preimplantation Genetic Diagnosis and Screening This technical update has been prepared by the Genetics Committee and approved by the
More informationUCLA UCLA Previously Published Works
UCLA UCLA Previously Published Works Title Recent advances in preimplantation genetic diagnosis and screening. Permalink https://escholarship.org/uc/item/6gc712qc Journal Journal of assisted reproduction
More informationScientific and Clinical Advances Advisory Committee Paper
Scientific and Clinical Advances Advisory Committee Paper Paper title Paper number SCAAC(06/15)07 Meeting date 10 June 2015 Agenda item 7 Author Information/decision Resource implications Implementation
More informationComparison of development and implantation of human embryos biopsied with two different methods: aspiration and displacement
Comparison of development and implantation of human embryos biopsied with two different methods: aspiration and displacement Wei-Hua Wang, Ph.D., Khalied Kaskar, M.S., Yuhong Ren, M.S., Jimmy Gill, M.D.,
More informationIncidence of Chromosomal Abnormalities from a Morphologically Normal Cohort of Embryos in Poor- Prognosis Patients
Incidence of Chromosomal Abnormalities from a Morphologically Normal Cohort of Embryos in Poor- Prognosis Patients M. C. MAGLI,1 L. GIANAROLI,1,3 S. MUNNE,2 and A. P. FERRARETTI1 Submitted: December 29,
More informationBlastocentesis: innovation in embryo biopsy
Blastocentesis: innovation in embryo biopsy L. Gianaroli, MC Magli, A. Pomante, AP Ferraretti S.I.S.Me.R. Reproductive Medicine Unit, Bologna, Italy Bologna, 8-11 May 2016 www.iiarg.com www.sismer.it 2013
More informationA Stepwise Approach to Embryo Selection and Implantation Success
Precise Genetic Carrier Screening An Overview A Stepwise Approach to Embryo Selection and Implantation Success Put today s most advanced genetic screening technology to work for you and your family s future.
More informationComprehensive chromosome screening is highly predictive of the reproductive potential of human embryos: a prospective, blinded, nonselection study
ORIGINAL ARTICLES: ASSISTED REPRODUCTION Comprehensive chromosome screening is highly predictive of the reproductive potential of human embryos: a prospective, blinded, nonselection study Richard T. Scott
More informationNew methods for embryo selection: NGS and MitoGrade
New methods for embryo selection: NGS and MitoGrade Santiago Munné, PhD US: Livingston, Los Angeles, Chicago, Portland, Miami / Europe: Barcelona (Spain), Oxford (UK), Hamburg (Germany) / Asia: Kobe (Japan),
More informationORIGINAL ARTICLE Reproductive genetics
Human Reproduction, Vol.28, No.5 pp. 1426 1434, 2013 Advanced Access publication on March 10, 2013 doi:10.1093/humrep/det053 ORIGINAL ARTICLE Reproductive genetics Polar body analysis by array comparative
More informationPreimplantation genetic testing
Follow the link from the online version of this article to obtain certified continuing medical education credits Preimplantation genetic testing Paul R Brezina, 1 Dawn S Brezina, 2 William G Kearns 3 4
More informationValidation of Next-Generation Sequencer for 24-Chromosome Aneuploidy Screening in Human Embryos
GENETIC TESTING AND MOLECULAR BIOMARKERS Volume 21, Number 11, 2017 ª Mary Ann Liebert, Inc. Pp. 1 7 DOI: 10.1089/gtmb.2017.0108 ORIGINAL ARTICLE Validation of Next-Generation Sequencer for 24-Chromosome
More informationNew perspectives on embryo biopsy, not how, but when and why PGS
New perspectives on embryo biopsy, not how, but when and why PGS Kangpu Xu, PhD Director, Laboratory of Preimplantation Genetics Center for Reproductive Medicine Weill Cornell Medical College of Cornell
More informationUvA-DARE (Digital Academic Repository) Preimplantation genetic screening: a reappraisal Mastenbroek, S. Link to publication
UvA-DARE (Digital Academic Repository) Preimplantation genetic screening: a reappraisal Mastenbroek, S. Link to publication Citation for published version (APA): Mastenbroek, S. (2011). Preimplantation
More informationUCL Centre for PGD, Institute for Women s Health, University College
QC standards in PGD and PGS. SenGupta, S.B 1, 2., Dhanjal, S 1. and Harper 1, J.C. 1 UCL Centre for PGD, Institute for Women s Health, University College London, 89-96 Chenies Mews, London WC1E 6HX, UK
More informationDiagnostic Techniques to Improve the Assessment of Human IVF Embryos: Genomics and Proteomics
Diagnostic Techniques to Improve the Assessment of Human IVF Embryos: Genomics and Proteomics Mandy G Katz-Jaffe Introduction A fundamental component of assisted reproductive technologies (ART) is the
More informationPGS & PGD. Preimplantation Genetic Screening Preimplantation Genetic Diagnosis
1 PGS & PGD Preimplantation Genetic Screening Preimplantation Genetic Diagnosis OUR MISSION OUR MISSION CooperGenomics unites pioneering leaders in reproductive genetics, Reprogenetics, Recombine, and
More informationArray comparative genomic hybridization screening in IVF significantly reduces number of embryos available for cryopreservation
ORIGINAL ARTICLE http://dx.doi.org/10.5653/cerm.2012.39.2.52 pissn 2233-8233 eissn 2233-8241 Clin Exp Reprod Med 2012;39(2):52-57 Array comparative genomic hybridization screening in IVF significantly
More informationASSISTED REPRODUCTION TECHNOLOGIES. Martin D. Keltz & Mario Vega & Ido Sirota & Matthew Lederman & Erin L. Moshier & Eric Gonzales & Daniel Stein
J Assist Reprod Genet (2013) 30:1333 1339 DOI 10.1007/s10815-013-0070-6 ASSISTED REPRODUCTION TECHNOLOGIES Preimplantation Genetic Screening (PGS) with Comparative Genomic Hybridization (CGH) following
More informationArticles Polar body-based preimplantation diagnosis for X-linked disorders
RBMOnline - Vol 4. No 1. 38 42 Reproductive BioMedicine Online; www.rbmonline.com/article/384 on web 20 November 2001 Articles Polar body-based preimplantation diagnosis for X-linked disorders Dr Yury
More informationCongreso Nacional del Laboratorio Clínico 2016
Actualización en Screening Genético Preimplantacional Maria Giulia Minasi Center for Reproductive Medicine European Hospital Rome, Italy Aneuploidy rate can reach 60% in human embryos Aneuploidy increases
More informationPreimplantation genetic diagnosis
Preimplantation genetic diagnosis Borut Peterlin Clinical institute of medical genetics, University Medical Centre Ljubljana Outline of the presentation Primary prevention of genetic diseases Motivation
More informationPaul R. Brezina, Raymond Anchan & William G. Kearns
Preimplantation genetic testing for aneuploidy: what technology should you use and what are the differences? Paul R. Brezina, Raymond Anchan & William G. Kearns Journal of Assisted Reproduction and Genetics
More informationOutcomes of preimplantation genetic diagnosis in neurofibromatosis type 1
Outcomes of preimplantation genetic diagnosis in neurofibromatosis type 1 The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation
More informationIVF AND PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) WHAT THE COMMUNITY PHYSICIAN NEEDS TO KNOW
IVF AND PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) WHAT THE COMMUNITY PHYSICIAN NEEDS TO KNOW Jon Havelock, MD, FRCSC, FACOG Co-Director - PCRM Disclosure No conflict of interest in relation
More informationComprehensive chromosome screening and embryo biopsy: advantages and difficulties. Antonio Capalbo, PhD Italy
Comprehensive chromosome screening and embryo biopsy: advantages and difficulties Antonio Capalbo, PhD Italy Disclosure Antonio Capalbo, PhD GEERA, Reproductive medicine centers GEETYX, molecular genetics
More informationPreimplantation Genetic Testing Where are we going? Genomics Clinical Medicine Symposium Sept 29,2012 Jason Flanagan, MS,CGC
Preimplantation Genetic Testing Where are we going? Genomics Clinical Medicine Symposium Sept 29,2012 Jason Flanagan, MS,CGC Overview Discuss what PGD and PGS are Pt examples What we have learned Where
More informationComprehensive Chromosome Screening Is NextGen Likely to be the Final Best Platform and What are its Advantages and Quirks?
Comprehensive Chromosome Screening Is NextGen Likely to be the Final Best Platform and What are its Advantages and Quirks? Embryo 1 Embryo 2 combine samples for a single sequencing chip Barcode 1 CTAAGGTAAC
More informationThe relationship between blastocyst morphology, chromosomal abnormality, and embryo gender
IN VITRO FERTILIZATION The relationship between blastocyst morphology, chromosomal abnormality, and embryo gender Samer Alfarawati, M.S. a,b Elpida Fragouli, Ph.D., a,b Pere Colls, Ph.D., c John Stevens,
More informationValidation of a next-generation sequencing based protocol for 24-chromosome aneuploidy screening of blastocysts
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 Q3 Q1 Q2 ORIGINAL ARTICLE: GENETICS
More informationCouples undergoing in vitro fertilization
Current Methods for Preimplantation Genetic Diagnosis Zachary P. Demko, Ph.D., Matthew Rabinowitz, Ph.D., and David Johnson, Ph.D. Gene Security Network, Redwood City, CA Corresponding Author: David Johnson,
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,800 116,000 120M Open access books available International authors and editors Downloads Our
More informationNEXCCS. Your guide to aneuploidy screening
NEXCCS Your guide to aneuploidy screening GROWING FAMILIES What is comprehensive chromosome screening? Comprehensive chromosome screening (CCS), also known as preimplantation genetic screening (PGS) or
More informationArticle Which patients with recurrent implantation failure after IVF benefit from PGD for aneuploidy screening?
RBMOnline - Vol 12. No 3. 2006 334-339 Reproductive BioMedicine Online; www.rbmonline.com/article/1947 on web 25 January 2006 Article Which patients with recurrent implantation failure after IVF benefit
More information24sure TM Setting new standards in IVF
24sure TM Setting new standards in IVF 24sure TM The clinical challenge While in vitro fertilization (IVF) is a highly successful medical intervention that has revolutionized the treatment of infertility,
More informationKent Academic Repository
Kent Academic Repository Full text document (pdf) Citation for published version Gould, Rebecca L and Griffin, Darren K. (2017) Karyomapping and how is it improving preimplantation genetics? Expert Review
More informationPregnancy outcomes following 24-chromosome preimplantation genetic diagnosis in couples with balanced reciprocal or Robertsonian translocations
Pregnancy outcomes following 24-chromosome preimplantation genetic diagnosis in couples with balanced reciprocal or Robertsonian translocations Dennis Idowu, M.D., a Katrina Merrion, M.S., b Nina Wemmer,
More informationRole of Preimplantation Genetic Diagnosis (PGD) in Current Infertility Practice
IJIFM REVIEW ARTICLE Role of Preimplantation Genetic Diagnosis (PGD) in Current Infertility Practice Role of Preimplantation Genetic Diagnosis (PGD) in Current Infertility Practice Helen Ghislaine Tempest,
More informationTABLE 1. Both the family and the Ethical Commission of the hospital were informed about and consented to the application of the DF-DGP.
CASE REPORT Outcome of twin babies free of Von Hippel Lindau disease after a double-factor preimplantation genetic diagnosis: monogenetic mutation analysis and comprehensive aneuploidy screening Albert
More informationMALBAC Technology and Its Application in Non-invasive Chromosome Screening (NICS)
MALBAC Technology and Its Application in Non-invasive Chromosome Screening (NICS) The Power of One Adapted from Internet Single Cell Genomic Studies Ultra Low Sample Input Advances and applications of
More informationFrom the earliest years of IVF, it
24-chromosome copy number analysis: a comparison of available technologies Alan H. Handyside, M.A., Ph.D. Bluegnome, Fulbourn, Cambridge; and Institute of Integrative and Comparative Biology, University
More informationA BS TR AC T. n engl j med 357;1 july 5, 2007
The new england journal of medicine established in 1812 july 5, 2007 vol. 357 no. 1 In Vitro Fertilization with Preimplantation Genetic Screening Sebastiaan Mastenbroek, M.Sc., Moniek Twisk, M.D., Jannie
More informationPre-implantation genetic diagnosis and pre-implantation genetic screening: two years experience at a single center
Original Article Obstet Gynecol Sci 2018;61(1):95-101 https://doi.org/10.5468/ogs.2018.61.1.95 pissn 2287-8572 eissn 2287-8580 Pre-implantation genetic diagnosis and pre-implantation genetic screening:
More informationArticle Pre-embryonic diagnosis for Sandhoff disease
RBMOnline - Vol 12. No 3. 2006 328-333 Reproductive BioMedicine Online; www.rbmonline.com/article/2100 on web 9 January 2006 Article Pre-embryonic diagnosis for Sandhoff disease Dr Anver Kuliev received
More informationPreimplantation genetic diagnosis: current status and new developments
Human Reproduction vol.12 no.8 pp.1756 1761, 1997 Preimplantation genetic diagnosis: current status and new developments Willy Lissens 1 and Karen Sermon However, owing to the risk of misdiagnosis (one
More informationPreimplantation Genetic Diagnosis (PGD) in Western Australia
Preimplantation Genetic Diagnosis (PGD) in Western Australia Human somatic cells have 46 chromosomes each, made up of the 23 chromosomes provided by the egg and the sperm cell from each parent. Each chromosome
More informationDNA Microarray Reveals That High Proportions of Human Blastocysts from Women of Advanced Maternal Age Are Aneuploid and Mosaic 1
BIOLOGY OF REPRODUCTION (2012) 87(6):148, 1 9 Published online before print 7 November 2012. DOI 10.1095/biolreprod.112.103192 DNA Microarray Reveals That High Proportions of Human Blastocysts from Women
More informationSingle Cell Whole Genome Amplification Technique Impacts the Accuracy of SNP Microarray Based Genotyping and Copy Number Analyses
Mol. Hum. Reprod. Advance Access published December 21, 2010 1 Single Cell Whole Genome Amplification Technique Impacts the Accuracy of SNP Microarray Based Genotyping and Copy Number Analyses Nathan R.
More informationAlexia Chatziparasidou, Martine Nijs, Martha Moisidou, Oraiopoulou Chara, Christina Ioakeimidou, Christos Pappas, Nicos Christoforidis
SHORT RESEARCH ARTICLE Accumulation of oocytes and/or embryos by vitrification: a new strategy for managing poor responder patients undergoing pre implantation diagnosis [version 2; referees: 2 approved,
More informationSingle-cell whole-genome amplification technique impacts the accuracy of SNP microarray-based genotyping and copy number analyses
Molecular Human Reproduction, Vol.17, No.6 pp. 335 343, 2011 Advanced Access publication on December 21, 2010 doi:10.1093/molehr/gaq103 NEW RESEARCH HORIZON Review Single-cell whole-genome amplification
More informationCurrent value of preimplantation genetic aneuploidy screening in IVF
Human Reproduction Update, Vol.13, No.1 pp. 15 25, 2007 Advance Access publication September 7, 2006 doi:10.1093/humupd/dml043 Current value of preimplantation genetic aneuploidy screening in IVF P.Donoso
More informationApplication of OMICS technologies on Gamete and Embryo Selection
Application of OMICS technologies on Gamete and Embryo Selection Denny Sakkas, Ph.D. Scientific Director, Boston IVF Waltham, MA, USA THE FUTURE ROLE OF THE EMBRYOLOGIST WILL FOCUS ON PROVIDING OUR PATIENTS
More informationS.Kahraman 1,4, M.Bahçe 2,H.Şamlı 3, N.İmirzalıoğlu 2, K.Yakısn 1, G.Cengiz 1 and E.Dönmez 1
Human Reproduction vol.15 no.9 pp.2003 2007, 2000 Healthy births and ongoing pregnancies obtained by preimplantation genetic diagnosis in patients with advanced maternal age and recurrent implantation
More information@ CIC Edizioni Internazionali. Origin and mechanisms of aneuploidies in preimplantation embryos
Review article Preimplantation genetic screening: definition, role in IVF, evolution and future perspectives Antonio Capalbo 1 Cristina Poggiana 1 Cristina Patassini 1 Anna Cecchele 1 Emiliano Scepi 1
More informationMedical Policy Preimplantation Genetic Testing
Medical Policy Preimplantation Genetic Testing Document Number: 004 Commercial* and Connector/ Qualified Health Plans Authorization required X No notification or authorization Not covered * Not all commercial
More informationCase report: Pregnancy After Vitrification of Biopsied Human Blastocysts Previously Frozen by the Slow Method
Case report: Pregnancy After Vitrification of Biopsied Human Blastocysts Previously Frozen by the Slow Method Batwala, M., Wilding, M., Create Fertility, Cheapside, London, UK Dalapati, T., University
More informationArticle Preimplantation diagnosis and HLA typing for haemoglobin disorders
RBMOnline - Vol 11. No 3. 2005 362-370 Reproductive BioMedicine Online; www.rbmonline.com/article/1853 on web 20 July 2005 Article Preimplantation diagnosis and HLA typing for haemoglobin disorders Dr
More informationCIC Edizioni Internazionali. Preimplantation genetic screening: definition, role in IVF, evolution and future perspectives. Summary.
Mini-review Preimplantation genetic screening: definition, role in IVF, evolution and future perspectives Antonio Capalbo 1 Cristina Poggiana 2 Cristina Patassini 2 Anna Checchele 2 Emiliano Scepi 2 Danilo
More informationPre-Implantation Genetic Diagnosis. Bradley Kalinsky, MD Amanda Kalinsky, RN, BSN
Pre-Implantation Genetic Diagnosis Bradley Kalinsky, MD Amanda Kalinsky, RN, BSN Our Clinical Vignette A young couple in the mid-to-late twenties presents to your clinic to discuss having children. The
More informationThe preventative role of preimplantation genetic diagnosis?
The preventative role of preimplantation genetic diagnosis? Alison Lashwood Consultant Genetic Counsellor & Clinical Lead in PGD PGDGenetics@gstt.nhs.uk www.pgd.org.uk Where it all starts.. Kay & John
More informationArticle Preimplantation genetic diagnosis of numerical abnormalities for 13 chromosomes
RBMOnline - Vol 6. No 2. 226 231 Reproductive BioMedicine Online; www.rbmonline.com/article/794 on web 28 January 2003 Article Preimplantation genetic diagnosis of numerical abnormalities for 13 chromosomes
More informationDiagnosis of parental balanced reciprocal translocations by trophectoderm biopsy and comprehensive chromosomal screening
Diagnosis of parental balanced reciprocal translocations by trophectoderm biopsy and comprehensive chromosomal screening Lian Liu, MD Co-Authors: L. W. Sundheimer1, L. Liu2, R. P. Buyalos1,3, G. Hubert1,3,
More informationPreimplantation genetic diagnosis of haemophilia
review Preimplantation genetic diagnosis of haemophilia Stuart Lavery Hammersmith Hospital, Imperial College, London, UK Summary Preimplantation genetic diagnosis (PGD) aims to increase the number of options
More informationRandomized comparison of next-generation sequencing and array comparative genomic hybridization for preimplantation genetic screening: a pilot study
Yang et al. BMC Medical Genomics (2015) 8:30 DOI 10.1186/s12920-015-0110-4 RESEARCH ARTICLE Open Access Randomized comparison of next-generation sequencing and array comparative genomic hybridization for
More informationThe effects of PGS/PGT-A on IVF outcomes
The effects of PGS/PGT-A on IVF outcomes Raoul Orvieto M.D. - Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, Ramat Gan, Israel - The Tarnesby-Tarnowski Chair for Family Planning and
More informationPre-Implantation Genetic Diagnosis. Bradley Kalinsky, MD Amanda Kalinsky, RN, BSN
Pre-Implantation Genetic Diagnosis Bradley Kalinsky, MD Amanda Kalinsky, RN, BSN Our Clinical Vignette A young couple in the mid-to-late twenties presents to your clinic to discuss having children. The
More informationC H A P T E R Molecular Genetics Techniques for Preimplantation Genetic Diagnosis
Author, please provide citation of references 82, 83 in the text C H A P T E R Molecular Genetics 16 Techniques for Preimplantation Genetic Diagnosis Francesco Fiorentino, Gayle M Jones Introduction HISTORICAL
More informationBlastocyst Morphology Holds Clues Concerning The Chromosomal Status of The Embryo
Original Article Blastocyst Morphology Holds Clues Concerning The Chromosomal Status of The Embryo Rita de Cassia Savio Figueira, M.Sc. 1, Amanda Souza Setti, B.Sc. 1,, Daniela Paes Almeida Ferreira Braga,
More informationComprehensive molecular cytogenetic analysis of the human blastocyst stage
Human Reproduction Vol.23, No.11 pp. 2596 2608, 2008 Advance Access publication on July 29, 2008 doi:10.1093/humrep/den287 Comprehensive molecular cytogenetic analysis of the human blastocyst stage E.
More informationNext generation technologies for PGD and 24- chromosome aneuploidy testing. PGD s 25 Year Journey: What is next?
Scientific Program 10 May 2015- Sunday 08:30 Pre-Congress Course Next generation technologies for PGD and 24- chromosome aneuploidy testing Sponsored by Illumina (invite only) 14:00 Illumina Focus Group
More informationCHROMOSOMAL MICROARRAY (CGH+SNP)
Chromosome imbalances are a significant cause of developmental delay, mental retardation, autism spectrum disorders, dysmorphic features and/or birth defects. The imbalance of genetic material may be due
More informationPreimplantation Diagnosis for Sonic Hedgehog Mutation Causing Familial Holoprosencephaly
The new england journal of medicine brief report Preimplantation Diagnosis for Sonic Hedgehog Mutation Causing Familial Holoprosencephaly Yury Verlinsky, Ph.D., Svetlana Rechitsky, Ph.D., Oleg Verlinsky,
More informationDetection of aneuploidy in a single cell using the Ion ReproSeq PGS View Kit
APPLICATION NOTE Ion PGM System Detection of aneuploidy in a single cell using the Ion ReproSeq PGS View Kit Key findings The Ion PGM System, in concert with the Ion ReproSeq PGS View Kit and Ion Reporter
More information